Login to Your Account



Stallergenes, Greer in $120M U.S. Pact on Grass Allergy Drug

By Cormac Sheridan
Staff Writer

Thursday, October 31, 2013
Stallergenes SA could receive up to $120 million in regulatory and sales-based milestones from a U.S. commercialization agreement with Greer Laboratories Inc., involving its investigational grass allergy treatment Oralair.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription